EPRX Stock: What You Need to Know
Looking to invest in EPRX Stock? Here’s what you need to know! EPRX is a bio pharmaceutical company that engages in the development and commercialization of products for the treatment of human diseases. The company has a number of products in various stages of development, including treatments for cancer, fibrosis, and autoimmune diseases. If you’re looking to invest in EPRX Stock, here’s what you need to know.
What is EPRX Stock
EPRX is a biopharmaceutical company that engages in the development and commercialization of products for the treatment of human diseases. The company has a number of products in various stages of development, including treatments for cancer, fibrosis, and autoimmune diseases. EPRX is a publicly traded company on the NASDAQ exchange under the ticker symbol EPRX.
EPRX’s Products
EPRX’s lead product candidate is EPC-001, a treatment for idiopathic pulmonary fibrosis (IPF). IPF is a debilitating and often fatal lung disease for which there is no cure. EPC-001 is currently in Phase II clinical trials. The company also has a number of other products in various stages of development, including treatments for cancer, autoimmune diseases, and rare genetic disorders.
Recent Developments
In September 2018, EPRX announced that it had entered into a definitive agreement to be acquired by Pfizer Inc. (PFE) for $48 per share in cash, or a total of approximately $116 million. The acquisition is subject to customary closing conditions, including regulatory approvals. EPRX Stock Financials
For the fiscal year ended December 31, 2017, EPRX reported revenue of $21.0 million and net income of $13.0 million. As of September 30, 2018, EPRX had cash and cash equivalents of $93.0 million and no debt.
Analyst Recommendations
Analysts have a consensus rating of “Buy” on EPRX stock with a price target of $48.00 per share.
EPRX Stock Price
EPRX stock closed at $41.48 per share on November 16, 2018, up $0.03 from its previous close of $41.45 per share.
Should You Invest in EPRX Stock?
EPRX is a biopharmaceutical company with a number of products in various stages of development, including a treatment for idiopathic pulmonary fibrosis (IPF) that is currently in Phase II clinical trials. The company has strong financials and is being acquired by Pfizer Inc. for $48 per share in cash, or a total of approximately $116 million. Analysts have a consensus rating of “Buy” on EPRX stock with a price target of $48.00 per share. EPRX stock closed at $41.48 per share on November 16, 2018, up $0.03 from its previous close of $41.45 per share. If you’re looking to invest in EPRX Stock, here’s what you need to know!
EPRX Stock Risks
Risks associated with investing in EPRX stock include the risks inherent in the development and commercialization of pharmaceutical products, the risk that EPRX will not be acquired by Pfizer, and the risks associated with regulatory approvals.
The Bottom Line
If you’re looking to invest in EPRX stock, here’s what you need to know. EPRX is a biopharmaceutical company that engages in the development and commercialization of products for the treatment of human diseases. The company has a number of products in various stages of development, including treatments for cancer, fibrosis, and autoimmune diseases. EPRX is publicly traded on the NASDAQ exchange under the ticker symbol EPRX.
